Clinical Trials on Glycogen Storage Disease Type II;Pompe's Disease in Netherlands
Total 2132 results
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II;Pompe's DiseaseCzechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2Netherlands
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II Pompe DiseaseUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase DeficiencyUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Spark TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Italy, United Kingdom, Netherlands, France, Germany
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Netherlands
-
Genzyme, a Sanofi CompanyRecruitingGlycogen Storage Disease Type II | Pompe DiseaseHungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
-
University Medical Center GroningenUniversity of Oxford; University of the Faroe Islands; Stichting Stofwisselkracht and other collaboratorsCompleted
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Germany, Israel, Italy, Netherlands, Taiwan
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Netherlands
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Japan Tobacco Inc.CompletedType II HyperlipidaemiaNetherlands
-
Ultragenyx Pharmaceutical IncCompletedGSD1Netherlands, United States, Canada, Spain
-
Akros Pharma Inc.CompletedType II HyperlipidemiaNetherlands
-
Maastricht University Medical CenterUnilever R&DCompletedFasting | Fatty Liver, Nonalcoholic | Glycogen Depletion | Meal TimeNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Maastricht UniversityNot yet recruitingLung Cancer Stage I | Lung Cancer Stage IINetherlands
-
Rijnstate HospitalCompleted
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingHead and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage IIINetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedDiabetes Mellitus Type IINetherlands
-
GI DynamicsCompletedType II DiabetesNetherlands
-
Denali Therapeutics Inc.Enrolling by invitationMucopolysaccharidosis IIUnited States, Canada, Belgium, Czechia, Netherlands
-
The Netherlands Cancer InstituteDutch Cancer SocietyTerminatedLung Metastases | Lung Cancer Stage I | Lung Cancer Stage IINetherlands
-
University Hospital, EssenRecruitingNSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIABelgium, Germany, Netherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Heart FoundationCompletedFamilial HypercholesterolemiaNetherlands
-
GH Research Ireland LimitedRecruiting
-
Eline C. B. EskesRecruitingAsmd, Visceral TypeNetherlands
-
Nij Smellinghe HosptialCompletedLymphedema | Breast Cancer Stage II | Early Disease OnsetNetherlands
-
Maastricht University Medical CenterCompletedNeutral Lipid Storage DiseaseNetherlands
-
Gelre HospitalsCompletedGrade II and III Acute Lateral Ankle Ligament InjuriesNetherlands
-
AmgenCompletedType II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell LymphomaSpain, United States, Finland, France, Netherlands
-
Eline C. B. EskesRecruiting
-
University of PennsylvaniaRegeneron PharmaceuticalsCompleted
-
Prothya BiosolutionsCompletedHereditary Angioedema Type I | Angioneurotic EdemaNetherlands
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedC3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and IIINetherlands, Australia, Belgium
-
Erasmus Medical CenterAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Leiden University... and other collaboratorsRecruitingOligodendroglioma | Astrocytoma, Grade III | Astrocytoma, Grade II | Oligodendroglioma, AnaplasticNetherlands